Harmony Biosciences Holdings financials
$39.29−1.80%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $868.5M | $714.7M | $582.0M | $437.9M | $305.4M | $159.7M |
| Gross profit | $670.1M | $557.9M | $460.8M | $354.4M | $249.9M | $132.0M |
| Gross margin | 77.2% | 78.1% | 79.2% | 80.9% | 81.8% | 82.6% |
| Operating income | $208.5M | $190.8M | $192.0M | $120.2M | $87.5M | $17.0M |
| Net income | $158.7M | $145.5M | $128.9M | $181.5M | $34.6M | -$63.8M |
| Net margin | 18.3% | 20.4% | 22.1% | 41.4% | 11.3% | −40.0% |
| Diluted EPS | $2.71 | $2.51 | $2.13 | $2.97 | $0.58 | $-2.48 |
| EBITDA | $233.8M | $214.9M | $216.4M | $143.6M | $106.4M | $27.2M |
| Operating cash flow | $348.2M | $219.8M | $219.4M | $144.5M | $98.6M | -$3.0M |
| Free cash flow | $347.9M | $218.7M | $182.1M | $144.3M | $98.3M | -$3.0M |
| Diluted shares | 58.5M | 57.9M | 60.4M | 61.1M | 59.2M | 25.8M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $752.5M | $453.0M | $311.7M | $243.8M | $234.3M | $228.6M |
| Short-term investments | $22.8M | $14.2M | $41.8M | $79.3M | — | — |
| Total debt | $163.7M | $179.3M | $193.6M | $191.6M | $192.0M | $194.3M |
| Total assets | $1.27B | $999.2M | $811.4M | $673.9M | $433.4M | $427.1M |
| Total liabilities | $401.4M | $340.0M | $344.5M | $271.0M | $246.9M | $329.9M |
| Shareholders' equity | $870.2M | $659.2M | $467.0M | $402.8M | $186.5M | $97.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology